Change the world

J2HBiotech - Journey to Healthcare Solutions

R&D Pipeline

R&D Pipeline : Developing Innovative Drug Candidates

J2H Biotech’s R&D pipeline focuses on innovative small-molecule oral therapeutics targeting rare and intractable diseases, including MASH, IPF/RIPF, and multiple sclerosis. In addition, it incorporates cutting-edge targeted protein degradation (TPD) technology. By leveraging our proprietary OPTIFLEX® platform, we ensure fast and efficient drug development, progressing each project systematically from preclinical to clinical stages. Our efforts aim to provide better treatment options for patients in the global healthcare market.

PipelingTargetsIndicationsR&D Stage
DiscoveryAnimal POCPreclinicalPhase 1Phase 2
J2H-170211β-HSD1
(Small molecule)		MASH
99%
Detail View
  • A selective 11β-HSD1 inhibitor targeting metabolic-associated steatohepatitis (MASH)
  • Demonstrated improvements in liver function, dyslipidemia, fibrosis, and steatosis in preclinical studies.
  • Showed excellent safety and pharmacokinetic profiles in Phase 1 trials; Phase 2a completion targeted by 2025.

J2H-1702
J2H-1702
FDC		11β-HSD1
(Small molecule)		IPF / RIPF
58%
Detail View
  • A combination therapy for idiopathic pulmonary fibrosis (IPF) and radiation-induced pulmonary fibrosis (RIPF)
  • Reduces side effects of nintedanib and protects lung tissue through fibrosis inhibition.
  • Improves safety, convenience, and patient compliance.

J2H-1702 FDC
J2H-2002EGFR
(TPD)		NSCLC
58%
Detail View
  • A next-generation NSCLC therapy utilizing cutting-edge TPD technology.
  • Overcomes resistance commonly associated with EGFR-targeted small-molecule therapies.
  • Suppresses additional resistance mutations, offering an effective and durable treatment option.

J2H-2002
J2H-1801Small
molecule		Multiple
Sclerosis
64%
Detail View
  • A hybrid drug improving upon Tecfidera by reducing gastrointestinal issues and flushing
  • Designed for oral administration, metabolizing into active MMF while maintaining efficacy and minimizing side effects.
  • Features enhanced safety with unique ingredient elimination.
J2H-1802Nrf2 activator
(Mutual prodrug)		IBD
30%
Detail View
  • A hybrid drug designed to combine the localized anti-inflammatory action of 5-ASA with the systemic immunomodulatory and antioxidant effects of MMF for complementary efficacy.
  • Demonstrated statistically significant reductions in TNF-α, IL-1β, IL-6, and MPO levels in a DSS-induced IBD disease model.
J2H-2104Nrf2 activator
(Small molecule)		Atopic dermatitis
Osteoartritis
19%
J2H-2301Novel target
(Small molecule)		Solid tumor
22%

Through our innovative R&D pipeline, J2H Biotech is committed to advancing transformative therapies
and addressing unmet medical needs, bringing hope and better outcomes to patients worldwide.